| Autor: |
Maryam Hajimoradi, Babak Sharif Kashani, Farzaneh Dastan, Sina Aghdasi, Atefeh Abedini, Farah Naghashzadeh, Arezoo Mohamadifar, Mohammad Sadegh Keshmiri, Sima Noorali, Somayeh Lookzadeh, Niloufar Alizadeh, Mohammad Amin Siri, Mohammadali Tavasolpanahi, Yazdan Abdolmohammadi, Masoud Shafaghi, Zahra Sadat Rouhani, Shadi Shafaghi |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Pharmacology, Vol 13 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1663-9812 |
| DOI: |
10.3389/fphar.2022.1107198 |
| Popis: |
Background: Remdesivir is effective against SARS-Cov-2 with little evidence of its adverse effect on the cardiac system. The aim of the present study is investigating the incidence of bradycardia in COVID-19 patients treated with Remdesivir.Methods: This prospective longitudinal study was conducted in a tertiary center on COVID-19 patients for Remdesivir therapy. The objectives were to investigate the incidence of sinus bradycardia, and also the association between their demographics, underlying diseases, and the disease severity with developing bradycardia in COVID-19 patients treated with Remdesivir.Results: Of 177 patients, 44% were male. The mean (±standard deviation) age of patients was 49.79 ± 15.16 years old. Also, 33% were hospitalized due to more severe symptoms. Oxygen support was required for all hospitalized subjects. A total of 40% of the patients had comorbidities, with the most common comorbidity being hypertension. The overall incidence of bradycardia (heart rate50 mg/L, O2 saturation |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
